For research use only. Not for therapeutic Use.
RBN-3143 is a potent and NAD+-competitive catalytic PARP14 inhibitor with an IC50 value of 4 nM. RBN-3143 inhibits PARP14-mediated ADP-ribosylation and stabilizes PARP14 in cell lines. RBN-3143 can be used in research of lung inflammation[1].
RBN-3143 (5 μg; intranasal administration) can improve steroid-resistant asthma mouse models[1].
Catalog Number | I042293 |
CAS Number | 2360853-16-1 |
Synonyms | 7-[(1-acetylpiperidin-4-yl)methoxy]-5-fluoro-2-(oxan-4-ylsulfanylmethyl)-3H-quinazolin-4-one |
Molecular Formula | C22H28FN3O4S |
Purity | ≥95% |
InChI | InChI=1S/C22H28FN3O4S/c1-14(27)26-6-2-15(3-7-26)12-30-16-10-18(23)21-19(11-16)24-20(25-22(21)28)13-31-17-4-8-29-9-5-17/h10-11,15,17H,2-9,12-13H2,1H3,(H,24,25,28) |
InChIKey | LLXIEISWIFSUBQ-UHFFFAOYSA-N |
SMILES | CC(=O)N1CCC(CC1)COC2=CC3=C(C(=C2)F)C(=O)NC(=N3)CSC4CCOCC4 |
Reference | [1]. Niepel M, et, al. The PARP14 inhibitor RBN-3143 suppresses lung inflammation in preclinical models. European Respiratory Journal 2022 60: 4642. |